拉贝洛尔、硫酸镁联合硝苯地平治疗子痫前期的效果及安全性分析

目的分析拉贝洛尔、硫酸镁联合硝苯地平治疗子痫前期的效果及安全性。方法72例子痫前期患者,采用随机信封法分为对照组与观察组,每组36例。对照组患者采用硫酸镁联合硝苯地平治疗,观察组患者采取拉贝洛尔、硫酸镁联合硝苯地平治疗。对比两组患者治疗前后24 h蛋白尿定量水平与血压情况、不良反应发生率。结果治疗前,两组患者24 h蛋白尿定量、收缩压及舒张压对比差异无统计学意义(P>0.05);治疗后,观察组患者24 h蛋白尿定量(1.29±0.35)g/24 h、收缩压(129.25±15.73)mm Hg(1 mm Hg=0.133 kPa)及舒张压(81.35±9.62)mm Hg均低于对照组的(1.97±0.73)g/24 h、(140.47±17.57)mm Hg、(93.61±9.05)mm Hg,差异有统计学意义(P<0.05)。观察组患者不良反应发生率为8.33%,对照组患者不良反应发生率为27.78%;观察组患者不良反应发生率明显低于对照组,差异有统计学意义(P<0.05)。结论拉贝洛尔、硫酸镁联合硝苯地平治疗子痫前期的效果及安全性更为明显,值得加以推广。

Analysis of effect and safety of labetalol,magnesium sulfate and nifedipine in the treatment of preeclampsia

Objective To analyze the effect and safety of labetalol,magnesium sulfate and nifedipine in the treatment of preeclampsia.Methods A total of 72 preeclampsia patients were divided into control group and observation group by random envelope method,with 36 cases in each group.The control group was treated by magnesium sulfate and nifedipine,and the observation group was treated by labetalol,magnesium sulfate and nifedipine.24 h urinary protein level and blood pressure before and after treatment and occurrence of adverse reactions were compared between the two groups.Results Before treatment,there was no statistically significant difference in 24 h urinary protein,systolic blood pressure and diastolic blood pressure between the two groups(P>0.05).After treatment,24 h urinary protein(1.29±0.35)g/24 h,systolic blood pressure(129.25±15.73)mm Hg(1 mm Hg=0.133 k Pa)and diastolic blood pressure(81.35±9.62)mm Hg of the observation group were lower than those of the control group(1.97±0.73)g/24 h,(140.47±17.57)mm Hg and(93.61±9.05)mm Hg,and the difference was statistically significant(P<0.05).The incidence of adverse reactions of the observation group was 8.33%,which was 27.78%of the control group.The incidence of adverse reactions of the observation group was obviously lower than that of the control group,and the difference was statistically significant(P<0.05).Conclusion Combination of labetalol,magnesium sulfate and nifedipine shows more obvious efficacy and safety in the treatment of preeclampsia,and it is worthy of promotion.